Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results

被引：0

作者：

Uy, Geoffrey L. ^{[1
]}

Pullarkat, Vinod A. ^{[2
]}

Baratam, Praneeth ^{[3
]}

Stuart, Robert K. ^{[3
]}

Faderl, Stefan ^{[4
]}

Chandrasekaran, Vijayalakshmi ^{[4
]}

Wang, Qi ^{[4
]}

Chakravarthy, Divya ^{[4
]}

Cheung, Ronald S. ^{[4
]}

Lin, Tara L. ^{[5
]}

机构：

[1] Washington Univ Sch Med, Div Oncol, St Louis, MO USA

[2] City Hope Comprehens Canc Ctr, Duarte, CA USA

[3] Med Univ South Carolina, Charleston, SC USA

[4] Jazz Pharmaceut, Palo Alto, CA USA

[5] Univ Kansas, Med Ctr, Kansas City, KS USA

来源：

关键词：

D O I：

10.1182/blood-2021-148455

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2316

引用

页数：5